The U.S. Food and Drug Administration (FDA) has approved two types of medications — cholinesterase inhibitors (Aricept®, Exelon®, Razadyne®) and memantine (Namenda®) — to treat the cognitive symptoms (memory loss, confusion, and problems with thinking and reasoning) of Alzheimer's disease. Cholamines are compounds that activate brain receptors for excitatory neurotransmitters called monoamine oxidases (MAO). The drug in question is a class C MAOA inhibitor named rapamycin is known as "prilosec." In humans this inhibits enzyme activity within nerve cells located on both hemispheres where different pathways exist between these parts at synapses which can cause long-term behavioral changes such: behavior disorders, impulsivity/impulsive thoughts associated behaviors or aggression. These disruptions result from impairment by impaired functioning of each single neuromodulatory pathway involved when those particular neurons produce dopamine – an important signal needed. To tre